Status: Recruiting
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Johnson & Johnson Private LimitedUpdated: Jul 31, 2026Locations: 11
Eligibility criteria
Participants who have definite diagnosis of active psoriatic arthritis (PsA) (ac... [+9]
History of latent or active granulomatous infection prior to screening [+4]